Nu-Med Plus (NUMD) EBITDA Margin (2021)
Nu-Med Plus' EBITDA Margin history spans 1 years, with the latest figure at 2670.22% for Q2 2021.
- Quarterly results put EBITDA Margin at 2670.22% for Q2 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was 8845.69% (changed N/A YoY), and the annual figure for FY2025 was 677.39%, down 58569.0%.
- EBITDA Margin for Q2 2021 was 2670.22% at Nu-Med Plus.
- In the past five years, EBITDA Margin ranged from a high of 2670.22% in Q2 2021 to a low of 2670.22% in Q2 2021.